American Academy of Neurology (AAN) Annual Meeting Archives

Phase III Results Set Neurocrine Up for Huntington’s Chorea sNDA

American Academy of Neurology (AAN) Annual Meeting, Brain Diseases, Chorea, Clinical Trials, Dyskinesia, Genetic Brain Disease, Huntington’s Disease, Movement Disorders, R&D, Supplemental New Drug Application (sNDA), Therapeutics

Neurocrine Biosciences announced positive results from the company’s Phase III KINECT-HD study evaluating the efficacy of valbenazine in the treatment of chorea associated with Huntington’s Disease (HD).

April 1, 2022/by BioSpace

SK life science Presents Long-term Data on Cognitive and Psychiatric Adverse Events Associated with XCOPRI CV in Adults with Partial-Onset (Focal) Seizures at the AAN 2022 Annual Meeting

American Academy of Neurology (AAN) Annual Meeting, Central Nervous System Diseases, Clinical Studies, Clinical Trials, Epilepsy, Oncology, Partial-Onset Seizures, R&D

SK Life Science Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd. – an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders – will present data from a pooled analysis from studies C013/C017 OLEs and C021 evaluating the cognitive and psychiatric treatment-related adverse events during adjunctive treatment with anti-seizure medication XCOPRI® (cenobamate tablets) CV at the American Academy of Neurology Annual Meeting, held in-person in Seattle April 2–7, 2022.

March 31, 2022/by PR Newswire